Strong Pipeline and Financials Are Supporting Merck Stock Price

Merck (NYSE: MRK) stock price is only among few drug manufacturers that have generated positive momentum this year. Its share price rallied almost 9% year to date despite the threat of a new pricing policy. The stock is currently trading slightly below from 52-weeks high of $87.

MRK Merck & Co., Inc. daily Stock Chart

Merck stock price momentum is supported by its innovative products and solid financial numbers. The company has topped second-quarter revenue and earnings estimates by a wide margin.

Its revenue of $11.8 billion increased 15% year over year in the second quarter. The revenue growth is driven by Human Health Vaccines and Oncology.

Along with the revenue growth, its strategy of investing in high margin products is adding to earnings potential. The company has generated earnings growth of 17% in the second quarter from the previous year period.

Kenneth Frazier, Chairman, and Chief Executive Officer said, “Our results demonstrate the continued momentum of our business through the first half of the year. The results further show our focus on the kind of innovation that significantly improved health outcomes is paying off.”

Merck also appears like a good stock for dividend investors. The company offers an annual dividend of $2.20 per share, yielding around 2.65%. The company has increased dividends over the past eight successive years.

It had increased annual dividend by 14.5% in 2018. The investors are expecting similar dividend growth for this year.

Its financial outlook and strong product line offer a room for dividend growth.

Merck expects to generate full-year revenue in the range of $46.2 billion, significantly higher from revenue of $42 billion in the past year. The guidance for full-year earnings per share stands around $3.88, up from $2.32 in the previous year.

Despite the steady share price rally, the stock looks fairly priced based on valuations. Merck stock price is currently trading around 16 times to earnings compared to the industry average of 20 times. Overall, Merck appears like a good play for dividend and value investors.

All trading carries risk. Views expressed are those of the writers only. Past performance is no guarantee of future results. The opinions expressed in this Site do not constitute investment advice and independent financial advice should be sought where appropriate. This website is free for you to use but we may receive commission from the companies we feature on this site.

Based in Saudi Arabia, Siraj has a strong understanding of and passion for accounting and finance. He has worked for international clients for many years on several projects related to the stock market, equity research and other business, accounting and finance related projects. Siraj is a published financial analyst on the world's leading websites including SeekingAlpha, TheStreet, MSN, and others.

HTML Snippets Powered By : XYZScripts.com